Sign inJoin waitlistJoin the waitlist

Ghayas Issa

Chief, Section of Chronic Myeloid Leukemia · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Section of Chronic Myeloid Leukemia Division · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2014–2017
Mount Sinai Beth Israel Hospital
2011–2014
Dana-Farber Cancer Institute
2010–2011
Doctor of Medicine
2006–2010

Research

BET bromodomain inhibition as a therapeutic strategy to target c-Myc
Cell · 2011 · 2,410 citations
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Nature · 2023 · First of 24 authors · Corresponding · 458 citations
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology · 2021 · 294 citations

Hagop Kantarjian
151 papers
Nicholas Short
139 papers · 7 as a fellow
Elias Jabbour
135 papers
Tapan Kadia
135 papers
Courtney DiNardo
128 papers
Naval Daver
127 papers
Guillermo Garcia-Manero
112 papers
GB
Gautam Borthakur
108 papers
KS
Koji Sasaki
105 papers · 9 as a fellow
Marina Konopleva
71 papers
Musa Yilmaz
71 papers
Naveen Pemmaraju
70 papers

Clinical trials

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2025–2030
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2028
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2028
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2028